Observation on the effect of herombopag olamine tablet in the treatment of chemotherapy-induced thrombo-cytopenia after breast cancer surgery

Wang Chao; Zhang Junmei; Zhang Peng; Liu Li; Wang Xiaochun

doi:10.3760/j.issn.1673-4777.2025.05.014

Abstract：Objective To investigate the efficacy of herombopag olamine tablet in the treatment of chemo-therapy-induced thrombocytopenia(CIT)after breast cancer surgery.Methods A total of 120 patients with CIT caused by chemotherapy after breast cancer surgery diagnosed in Affiliated Hospital of Hebei University from December 2021 to December 2023 were selected.According to the random number table method,the patients were divided into recombinant human thrombopoietin(rhTPO)group and combined group,with 60 cases in each group.The rhTPO group was treated with rhTPO,and the combination group was treated with rhTPO and herombopag olamine tablets.Both groups were treated for 4 weeks.The clinical efficacy,platelet parameters,thrombopoietin(TPO),inflammatory factors,platelet count(PLT),immune function indexes and adverse reactions were compared between the two groups after treatment.Results The total effective rate in the combined group was significantly higher than that in the rhTPO group[91.7％(55/60)vs 75.0％(45/60)](P=0.014).After treatment,the platelet volume distribution width and mean platelet volume in the two groups were lower than those before treatment,and those in the combined group were lower than those in the rhTPO group,and the platelet crit was higher than that before treatment,and those in the combined group were higher than those in the rhTPO group(all P＜0.05).After treatment,the levels of IL-6,TPO and tumor necrosis factor-α in the two groups were lower than those before treatment,and those in the combined group were significantly lower than those in the rhTPO group(all P＜0.05).After 3,7 and 14 days of treatment,the PLT levels of the two groups were higher than those before treatment,and the PLT levels of the combined group were higher than those of the rhTPO group(all P＜0.05).Compared with before treatment,the levels of CD3+,CD4+,and CD4+/CD8+ratio in the two groups after treatment were significantly increased,and those in the combined group were higher than those in the rhTPO group(all P＜0.05).After treatment,there was no significant difference in the incidence of adverse reactions between the two groups(P=0.488).Conclusion Herombopag olamine tablet combined with rhTPO in the treatment of CIT caused by chemotherapy after breast cancer surgery can improve the clinical efficacy of patients,reduce the levels of serum interleukin-6,TPO and tumor necrosis factor-α,improve PLT and immune function,and has high safety.